Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT and Plasma Exchange + Tenofovir vs Tenofovir in ACLF-HBV
NCT04431375Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of Fecal Microbiota Transplantation Capsule and High-Volume Plasma Exchange + GCSF in acute-on-chronic liver failure (ACLF) and hepatitis B (HBV) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Overall survival at 28 days. Status: unknown.
02
Drugs
Fecal Microbiota Transplantation CapsuleHigh-Volume Plasma Exchange + GCSF
03
Conditions
acute-on-chronic liver failure (ACLF)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04431375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431375.